Am J Perinatol 2019; 36(01): 079-085
DOI: 10.1055/s-0038-1666974
SMFM Fellowship Series Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Number of Risk Factors in Down Syndrome Pregnancies

Deana J. Hussamy
1   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
,
Christina L. Herrera
1   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
,
Diane M. Twickler
1   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
2   Department of Radiology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
,
Donald D. Mcintire
1   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
,
Jodi S. Dashe
1   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, Texas
› Author Affiliations
Further Information

Publication History

21 February 2018

03 June 2018

Publication Date:
17 July 2018 (online)

Abstract

Objective The objective of this study was to evaluate risk factor prevalence in pregnancies with fetal Down syndrome, in an effort to characterize efficacy of population-based screening.

Study Design Retrospective review of singleton pregnancies with delivery of live born or stillborn infant with Down syndrome from 2009 through 2015. Risk factor categories included maternal age ≥35 years, abnormal serum screening, identification of ≥1 ultrasound marker at 16 to 22 weeks (nuchal thickness ≥6 mm, echogenic intracardiac focus, echogenic bowel, renal pelvis dilatation, femur length <third percentile), and detection of a major fetal anomaly. Statistical analyses included χ2 test and Mantel–Haenszel χ2 test.

Results Down syndrome infants represented 1:428 singleton births. All risk categories were assessed in 125 pregnancies and included abnormal serum screen in 110 (88%), ≥1 ultrasound marker in 66 (53%), and ≥1 anomaly in 41 (34%). The calculated risk was at least 1:270 in 93% of Down syndrome pregnancies. More pregnancies had multiple risk factors than had a single risk factor, 90 (72%) versus 30 (24%), p < 0.001. An abnormal ultrasound marker or anomaly was identified in >50% of fetuses in women <35 years and in >75% of those 35 years and older.

Conclusion In a population-based cohort, sensitivity of second-trimester Down syndrome screening was 93%, with multiple risk factors present in nearly three-fourths of cases.

Note

This study was presented at the Society for Maternal-Fetal Medicine 37th Annual Meeting, Las Vegas, NV.


 
  • References

  • 1 Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams MA. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998; 12 (01) 8-14
  • 2 Bromley B, Lieberman E, Shipp TD, Benacerraf BR. The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med 2002; 21 (10) 1087-1096
  • 3 Committee on Practice Bulletins—Obstetrics and the American Institute of Ultrasound in Medicine. Practice Bulletin No. 175: ultrasound in pregnancy. Obstet Gynecol 2016; 128 (06) e241-e256
  • 4 Practice Bulletin No. 163 Summary: screening for fetal aneuploidy. Obstet Gynecol 2016; 127 (05) 979-981
  • 5 Vintzileos AM, Egan JF. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography. Am J Obstet Gynecol 1995; 172 (03) 837-844
  • 6 Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology 1991; 181 (01) 129-133
  • 7 Cunningham FG, Leveno KJ, Bloom SL. , et al , eds. Williams Obstetrics, 25th ed. New York: McGraw-Hill; 2018: 286-287
  • 8 Bahado-Singh RO, Oz UA, Mendilcioglu I, Mahoney MJ. The mid-trimester genetic sonogram. Semin Perinatol 2005; 29 (04) 209-214
  • 9 Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH. Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41 (03) 247-261
  • 10 Morris JK, Garne E, Wellesley D. , et al. Major congenital anomalies in babies born with Down syndrome: a EUROCAT population-based registry study. Am J Med Genet A 2014; 164A (12) 2979-2986
  • 11 Rankin J, Tennant PW, Bythell M, Pearce MS. Predictors of survival in children born with Down syndrome: a registry-based study. Pediatrics 2012; 129 (06) e1373-e1381
  • 12 Stoll C, Dott B, Alembik Y, Roth MP. Associated congenital anomalies among cases with Down syndrome. Eur J Med Genet 2015; 58 (12) 674-680
  • 13 Hamilton BE, Martin JA, Osterman MJK, Curtin SC. Births: Preliminary Data for 2014. National Vital Statistics Reports; Vol 64 no 6. Hyattsville, MD: National Center for Health Statistics; 2015
  • 14 Loane M, Morris JK, Addor M-C. , et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 2013; 21 (01) 27-33
  • 15 Martin JA, Hamilton BE, Osterman MJK. Births in the United States, 2015. NCHS Data Brief, No 258. Hyattsville, MD: National Center for Health Statistics; 2016
  • 16 Mai CT, Kucik JE, Isenburg J. , et al; National Birth Defects Prevention Network. Selected birth defects data from population-based birth defects surveillance programs in the United States, 2006 to 2010: featuring trisomy conditions. Birth Defects Res A Clin Mol Teratol 2013; 97 (11) 709-725
  • 17 Malone FD, Canick JA, Ball RH. , et al; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353 (19) 2001-2011
  • 18 Baer RJ, Flessel MC, Jelliffe-Pawlowski LL. , et al. Detection rates for aneuploidy by first-trimester and sequential screening. Obstet Gynecol 2015; 126 (04) 753-759
  • 19 Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015; 45 (03) 249-266
  • 20 de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A 2015; 167A (04) 756-767
  • 21 Kuppermann M, Pena S, Bishop JT. , et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. JAMA 2014; 312 (12) 1210-1217
  • 22 Aagaard-Tillery KM, Malone FD, Nyberg DA. , et al; First and Second Trimester Evaluation of Risk Research Consortium. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009; 114 (06) 1189-1196